PHIO PHARMACEUTICALS CORP.
411 Swedeland Road, Suite 23-1080
King of Prussia, PA 19406
August 21, 2025
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jessica Dickerson
| Re: | Phio Pharmaceuticals Corp. |
| Registration Statement on Form S-3 | |
| Filed August 15, 2025 | |
| File No. 333-289621 | |
| Request for Acceleration of Effective Date |
Dear Ms. Dickerson:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 22, 2025, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted.
Very truly yours,
PHIO PHARMACEUTICALS CORP.
By: /s/ Robert J. Bitterman
Name: Robert J. Bitterman
Title: President and Chief Executive Officer
cc: Amanda Brown, Hogan Lovells US LLP